Literature DB >> 17215586

Hepcidin in anemia and inflammation in chronic kidney disease.

Jolanta Malyszko1, Michal Mysliwiec.   

Abstract

Maintaining the correct iron balance is crucial for health. Our understanding of the molecular control of iron metabolism has increased dramatically over the past 5 years due to the discovery of hepcidin. This is a circulating antimicrobial peptide mainly synthesized in the liver, which has been recently proposed as a factor regulating the uptake of dietary iron and its mobilization from macrophages and hepatic stores. Inflammation causes an increase of production of hepcidin, which is a potent mediator of anemia of chronic diseases. Anemia in chronic kidney disease is mainly due to erythropoietin deficiency but these patients often have a chronic inflammatory state. The aim of this review is to summarize the current knowledge dealing with a possible role of hepcidin in iron metabolism and its regulation, particularly in kidney disease. In addition, current methods of determination of hepcidin are reviewed. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17215586     DOI: 10.1159/000098522

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  35 in total

Review 1.  Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia.

Authors:  David M Charytan; Steven Fishbane; Jolanta Malyszko; Peter A McCullough; David Goldsmith
Journal:  Am J Kidney Dis       Date:  2015-02-26       Impact factor: 8.860

2.  Role of hepcidin and iron metabolism in the onset of prostate cancer.

Authors:  Bin Zhao; Ruiqian Li; Gang Cheng; Zhiyao Li; Zhiping Zhang; Jun Li; Guoying Zhang; Chengwei Bi; Chen Hu; Libo Yang; Yonghong Lei; Qilin Wang
Journal:  Oncol Lett       Date:  2018-04-20       Impact factor: 2.967

3.  Effectiveness of oral iron to manage anemia in long-term hemodialysis patients with the use of ultrapure dialysate.

Authors:  Akiyasu Tsuchida; Bishnuhari Paudyal; Pramila Paudyal; Yoshitaka Ishii; Keiju Hiromura; Yoshihisa Nojima; Minoru Komai
Journal:  Exp Ther Med       Date:  2010-07-20       Impact factor: 2.447

Review 4.  Ironing out the cross talk between FGF23 and inflammation.

Authors:  Valentin David; Connor Francis; Jodie L Babitt
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-31

Review 5.  Effectiveness of hypoxia-induced factor prolyl hydroxylase inhibitor for managing anemia in chronic kidney disease: a systematic review and meta-analysis.

Authors:  Min Li; Jiarong Lan; Feixia Dong; Peixin Duan
Journal:  Eur J Clin Pharmacol       Date:  2020-11-07       Impact factor: 2.953

6.  Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates.

Authors:  Jason S Troutt; Anthony M Butterfield; Robert J Konrad
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

Review 7.  Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis.

Authors:  Dengpiao Xie; Jianting Wang; Xinping Wu; Mingquan Li
Journal:  Int Urol Nephrol       Date:  2018-08-02       Impact factor: 2.370

8.  Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS.

Authors:  Natascia Campostrini; Annalisa Castagna; Federica Zaninotto; Valeria Bedogna; Nicola Tessitore; Albino Poli; Nicola Martinelli; Antonio Lupo; Oliviero Olivieri; Domenico Girelli
Journal:  J Biomed Biotechnol       Date:  2010-04-15

Review 9.  Biomarkers for lupus nephritis: a critical appraisal.

Authors:  Chi Chiu Mok
Journal:  J Biomed Biotechnol       Date:  2010-04-19

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.